{"pub": "financialpost", "url": "https://globenewswire.com/news-release/2019/10/07/1925740/0/en/MediPharm-Labs-Announces-Participation-at-Upcoming-BMO-TMX-Hemp-Medical-Cannabis-Conference-in-London-UK.html", "downloaded_at": "2019-10-07 12:12:19.005616+00:00", "title": "MediPharm Labs Announces Participation at Upcoming BMO & TMX Hemp & Medical Cannabis Conference in London, UK", "language": "en", "text": "TORONTO, Oct. 07, 2019 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (\u201cMediPharm Labs\u201d or the \u201cCompany\u201d) a global leader in specialized, research-driven cannabis extraction, distillation, purification and cannabinoid isolation, is pleased to announce its participation at the BMO & TMX Hemp & Medical Cannabis Conference in London, UK on October 16, 2019.\n\nPat McCutcheon, CEO of MediPharm Labs, will participate on a panel discussion that will provide an update on key medical cannabis markets in Europe. MediPharm Labs will be presenting alongside management representatives from Aurora Cannabis Inc. and Canopy Growth Corp. The Company will also be available for pre-scheduled one-on-one meetings during the conference.\n\nAbout MediPharm Labs Corp.\n\nFounded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical-like cannabis oil and concentrates and advanced derivative products utilizing a Good Manufacturing Practices designed facility and ISO standard built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities with five primary extraction lines having 300,000 kg of annual processing capacity to deliver pure, trusted and precisely-dosed cannabis products for its customers. Through its wholesale, white label and tolling platforms, they formulate, process, package and distribute cannabis extracts and advanced cannabinoid-based products to domestic and international markets. As a global leader, the Company also completed commercial exports to Australia and is nearing completion of its Australian extraction facility expected in 2019 with 75,000 kg of annual processing capacity.\n\nFor more information:\n\nLaura Lepore, VP, Investor Relations\n\nTelephone: 705-719-7425 ext 216\n\nEmail: investors@medipharmlabs.com\n\nWebsite: www.medipharmlabs.com\n\nCAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION:\n\nThis news release contains \u201cforward-looking information\u201d and \u201cforward-looking statements\u201d (collectively, \u201cforward-looking statements\u201d) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as \u201cexpects\u201d, or \u201cdoes not expect\u201d, \u201cis expected\u201d, \u201canticipates\u201d or \u201cdoes not anticipate\u201d, \u201cplans\u201d, \u201cbudget\u201d, \u201cscheduled\u201d, \u201cforecasts\u201d, \u201cestimates\u201d, \u201cbelieves\u201d or \u201cintends\u201d or variations of such words and phrases or stating that certain actions, events or results \u201cmay\u201d or \u201ccould\u201d, \u201cwould\u201d, \u201cmight\u201d or \u201cwill\u201d be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things, the completion of MediPharm Labs\u2019 Australian facility and timing thereof, and expected processing capacity of the Australian facility. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm Labs to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm Labs\u2019 filings, available on the SEDAR website at www.sedar.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm Labs assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.", "description": "", "authors": ["Medipharm Labs Corp."], "top_image": "http://www.globenewswire.com/Attachment/LogoDisplay/815473?filename=815473.jpg&size=1", "published_at": "2019-10-07"}